Foundation Venture Capital Group

Name

Foundation Venture Capital Group

Legal name

Foundation Venture Capital Group

Website

https://foundationventure.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Venture Capital / Health Technology Investment

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Impact / ESG Venture Capital (FSANAAAG)

akta.pro secondary industries

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA), Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure) (FSAAALAG), Healthcare Access & Life Sciences Impact Funds (FSANAJAI), Impact Investing & Social Finance (Funds, CDFIs, Microfinance) (BPAGALAA)

Keywords

• Venture capital funding
• Pre-seed investment
• Seed-stage investment
• Health technology startups
• Impact investing

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Investment Returns: Provides pre-seed and seed funding to health-related start-up companies with the intention to generate positive social impact. Any gains realized from investments are reinvested into furthering research and innovation at affiliated organizations. Returns support the evergreen investment model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Foundation Venture Capital Group uses impact investing to provide pre-seed and seed equity funding to health-related start-up companies spun out of affiliated New Jersey research institutions. In addition to capital, FVCG delivers nonmonetary support including strategic business guidance, operational assistance, and back-office management, with the goal of advancing these companies toward commercialization and subsequent traditional venture financing. Realized investment gains are recycled into further research and innovation at the affiliated organizations, creating an evergreen funding continuum.

Product overview

Foundation Venture Capital Group is a Princeton, New Jersey-based venture capital firm using impact investing to provide pre-seed and seed funding to health-related start-up companies. Rather than a unified software platform, FVCG operates as a funding and advisory organization offering two core products: pre-seed/seed funding and strategic business guidance. Their portfolio includes early-stage health technology companies across diagnostics, therapeutics, medical devices, and digital health sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Pre-Seed and Seed Funding Impact investing equity funding provided to health-related start-up companies at affiliated organizations to help them advance toward and through commercialization.
• Strategic Business Guidance and Operational Support Nonmonetary support provided to portfolio companies including strategic, operational, and back-office management assistance, beginning prior to incorporation and extending through the company lifecycle.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Hackensack Meridian HealthcoreStrategic or Co-development Partner · 1 January 2024FVCG committed $1 million to EValuate Diagnostics, the first spin-out company from Hackensack Meridian Health Research Institute and its Office of Innovation and Commercialization. EValuate Diagnostics markets a platform for targeted capture of circulating biomarkers for early disease detection.
• Princeton UniversitycoreStrategic or Co-development Partner · 1 January 2019Princeton University spinout Kayothera received initial seed funding from FVCG in 2019. Dr. Yibin Kang and Dr. Mark Esposito co-founded the company based on discoveries from Princeton research. FVCG continues to support the company's advancement toward commercialization.
• Rutgers UniversitycoreStrategic or Co-development PartnerMultiple Rutgers University spinouts have received FVCG funding including NemaGen Discoveries ($1MM investment for asthma/allergic disease therapies) and Zena Therapeutics ($1 million commitment for mental health and addiction medications). Rutgers researchers are eligible to apply for FVCG funding through affiliation agreements.
• Rutgers UniversitycoreStrategic or Co-development PartnerVisikol was founded and spun out of Rutgers University by Michael Johnson and Tom Villani. FVCG invested $500,000 in 2016 to develop proprietary tissue clearing reagents and software platform. Company was later acquired by CELLINK.
• New Jersey Health FoundationcoreOthersFVCG is an affiliate of the New Jersey Health Foundation (NJHF), a not-for-profit corporation that supports health-related research and education programs in New Jersey through Research/Community Health and Social Service grant programs. Researchers from affiliated organizations can apply for grants leading to FVCG investment.
• Foundation for Health AdvancementcoreOthersFVCG is affiliated with Foundation for Health Advancement which provides Innovation Grants to support early-stage university technologies with strong commercialization potential. This creates a continuum of funding from grants to venture investment.
• Cooper Healthcare SystemcoreStrategic or Co-development PartnerCooper Healthcare researchers and employees are eligible to apply for FVCG funding through Affiliation Agreements. FVCG supports Innovation Grant projects including antegrade artery entry device and wearable cardiac monitor development.
• NJIT (New Jersey Institute of Technology)coreStrategic or Co-development PartnerNJIT researchers are eligible to apply for FVCG funding through Affiliation Agreements. Supported projects include novel cancer drug testing platform development and minimally invasive palpation device research.
• Stevens Institute of TechnologycoreStrategic or Co-development PartnerStevens Institute researchers are eligible to apply for FVCG funding through Affiliation Agreements. Supported projects include minimally invasive palpation device and Trach Alert Project.
• Kessler FoundationcoreStrategic or Co-development PartnerKessler Foundation researchers and employees are eligible to apply for FVCG funding through Affiliation Agreements for health-related research and innovation projects.
• Rowan UniversitycoreStrategic or Co-development PartnerRowan University researchers and employees are eligible to apply for FVCG funding through Affiliation Agreements for health-related research and innovation commercialization.
• I-Corp ProgramminorGTM or Marketing PartnerZena Therapeutics was accepted to participate in the national I-Corp program, a federal program supporting technology commercialization, alongside receiving NJEDA NJ IGNITE program funding.

Scale indicators8 records

Recent moves9 records

Expansion highlights4 records

Direct peers

• BioAdvance: Pennsylvania-based early-stage venture fund investing in life sciences and healthcare technologies emerging from regional research institutions. Closely comparable in mission, stage focus, and university spinout sourcing model to FVCG.
• Osage University Partners (OUP): Venture firm that invests exclusively in university spinouts, partnering with research institutions to commercialize academic IP. Highly comparable to FVCG's model of sourcing pre-seed/seed investments exclusively from affiliated universities.
• Cure Ventures: Early-stage venture firm that partners with leading academic researchers to launch biotech startups from universities. Comparable in the model of building companies around academic spinouts, often co-investing with seed-stage syndicates like FVCG.
• Accelerator Life Science Partners (ALSP): Seattle/New York-based early-stage life science venture firm that led the $8M Series A in FVCG portfolio company KayoThera. Directly comparable as a healthcare/life science-focused early-stage investor, often partnering with pre-seed/seed funds like FVCG to provide next-stage capital.

Broad incumbents

• Frazier Life Sciences: Healthcare-dedicated venture firm investing across therapeutic platforms and companies at multiple stages. Comparable in healthcare focus and willingness to invest in early-stage spinouts, though with broader stage range and national reach.
• ARCH Venture Partners: Large, established early-stage science and technology venture firm with a long track record of university spinout investing. Operates at much greater scale than FVCG but shares the focus on commercializing breakthrough research from top research institutions.
• Atlas Venture: Boston-based early-stage life sciences venture firm that creates and invests in biotech startups. Comparable in stage focus (seed/Series A) and therapeutic orientation, though operating at significantly larger scale and broader geographic scope.

Emerging players

• BioGenerator: St. Louis-based nonprofit venture fund focused on creating and seeding life science startups from regional research institutions. Highly comparable as a smaller, mission-driven, regional seed-stage health investor with an impact orientation.

Others

• New Jersey Health Foundation (NJHF): Nonprofit parent/affiliate organization of FVCG that funds health-related research and education through grant programs. Provides the upstream portion of the funding continuum and shares the same impact-oriented health innovation mission.
• Foundation for Health Advancement: Sister organization within the same family of New Jersey health-focused nonprofits, providing Innovation Grants that feed into FVCG's investment pipeline. Comparable in mission and regional focus on translating NJ academic research into commercial ventures.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Foundation Venture Capital Group